S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
- Title
- Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
- Principal Investigator
- Safi, Danish
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Breast Cancer
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Kaitlyn Hager
- Research Nurse
- Email: kaitlyn.hager@hsc.wvu.edu